Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian Ford

Showing results (391-400 of 508) with videos related to

Pageof 51
Sort By:
Faraday Discussions|July 5, 2022
Controlling polymorphism: general discussionRuel Cedeno, Aurora Cruz-Cabeza, Rik Drummond-Brydson, et al.
Circulation. Cardiovascular Interventions|August 1, 2019
Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary SyndromeMatthew M Y Lee, Mark C Petrie, Paul Rocchiccioli, et al.
Open Heart|February 27, 2021
Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populationsMatthew M Y Lee, Mark C Petrie, Paul Rocchiccioli, et al.
Journal of the American College of Cardiology|April 9, 2025
Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-AnalysisAnoop S V Shah, Spencer J Keene, Lisa Pennells, et al.
European Journal of Heart Failure|April 14, 2016
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiencyStefan D Anker, Stefan Schroeder, Dan Atar, et al.
JAMA Cardiology|June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization AnalysisStephen Burgess, Brian A Ference, James R Staley, et al.
Circulation. Cardiovascular Interventions|February 19, 2020
One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention: The T-TIME Randomized TrialAnnette M Maznyczka, Peter J McCartney, Hany Eteiba, et al.
Nature Methods|June 23, 2014
Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomicsAlicia Lundby, Elizabeth J Rossin, Annette B Steffensen, et al.
European Journal of Heart Failure|June 22, 2016
Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]Stefan D Anker, Stefan Schroeder, Dan Atar, et al.
JAMA|January 9, 2019
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialPeter J McCartney, Hany Eteiba, Annette M Maznyczka, et al.
Pageof 51

Showing results (391-400 of 508) with videos related to

Sort By:
Pageof 51
Faraday Discussions|July 5, 2022
Controlling polymorphism: general discussionRuel Cedeno, Aurora Cruz-Cabeza, Rik Drummond-Brydson, et al.
Circulation. Cardiovascular Interventions|August 1, 2019
Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary SyndromeMatthew M Y Lee, Mark C Petrie, Paul Rocchiccioli, et al.
Open Heart|February 27, 2021
Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populationsMatthew M Y Lee, Mark C Petrie, Paul Rocchiccioli, et al.
Journal of the American College of Cardiology|April 9, 2025
Cardiac Troponins and Cardiovascular Disease Risk Prediction: An Individual-Participant-Data Meta-AnalysisAnoop S V Shah, Spencer J Keene, Lisa Pennells, et al.
European Journal of Heart Failure|April 14, 2016
Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiencyStefan D Anker, Stefan Schroeder, Dan Atar, et al.
JAMA Cardiology|June 22, 2018
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization AnalysisStephen Burgess, Brian A Ference, James R Staley, et al.
Circulation. Cardiovascular Interventions|February 19, 2020
One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention: The T-TIME Randomized TrialAnnette M Maznyczka, Peter J McCartney, Hany Eteiba, et al.
Nature Methods|June 23, 2014
Annotation of loci from genome-wide association studies using tissue-specific quantitative interaction proteomicsAlicia Lundby, Elizabeth J Rossin, Annette B Steffensen, et al.
European Journal of Heart Failure|June 22, 2016
Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]Stefan D Anker, Stefan Schroeder, Dan Atar, et al.
JAMA|January 9, 2019
Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialPeter J McCartney, Hany Eteiba, Annette M Maznyczka, et al.
Pageof 51